Journal article · 2022 · Open access
A targetable pathway in neutrophils mitigates both arterial and venous thrombosis
Science Translational Medicine, 14(660), eabj7465 · Published 31 August 2022 · DOI 10.1126/scitranslmed.abj7465
In brief
“A targetable pathway in neutrophils mitigates both arterial and venous thrombosis” is a 2022 journal article by Lalitha V. Nayak and 15 co-authors, published in Science Translational Medicine. OpenAlex counts 61 citations as of 19 November 2026, which puts it in the top 7% of works published in 2022 by citations. It is open access: the full text is free to read at PubMed Central.
- Citations
- 61
- Most cited in
- 2023 (15)
- Field-weighted impact
- 6.74
- References
- 44
- Authors
- 16
Abstract
Arterial and venous thrombosis constitutes a major source of morbidity and mortality worldwide. Long considered as distinct entities, accumulating evidence indicates that arterial and venous thrombosis can occur in the same populations, suggesting that common mechanisms are likely operative. Although hyperactivation of the immune system is a common forerunner to the genesis of thrombotic events in both vascular systems, the key molecular control points remain poorly understood. Consequently, antithrombotic therapies targeting the immune system for therapeutics gain are lacking. Here, we show that neutrophils are key effectors of both arterial and venous thrombosis and can be targeted through immunoregulatory nanoparticles. Using antiphospholipid antibody syndrome (APS) as a model for arterial and venous thrombosis, we identified the transcription factor Krüppel-like factor 2 (KLF2) as a key regulator of neutrophil activation. Upon activation through genetic loss of KLF2 or administration of antiphospholipid antibodies, neutrophils clustered P-selectin glycoprotein ligand 1 (PSGL-1) by cortical actin remodeling, thereby increasing adhesion potential at sites of thrombosis. Targeting clustered PSGL-1 using nanoparticles attenuated neutrophil-mediated thrombosis in APS and KLF2 knockout models, illustrating the importance and feasibility of targeting activated neutrophils to prevent pathological thrombosis. Together, our results demonstrate a role for activated neutrophils in both arterial and venous thrombosis and identify key molecular events that serve as potential targets for therapeutics against diverse causes of immunothrombosis.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Nayak, L. V., Sweet, D. R., Thomas, A., Lapping, S. D., Kalikasingh, K. A., Madera, A., Vinayachandran, V., Padmanabhan, R., Vasudevan, N. T., Myers, J., Huang, A. Y.-C., Schmaier, A. H., Mackman, N., Liao, X., Maiseyeu, A., & Jain, M. K. (2022). A targetable pathway in neutrophils mitigates both arterial and venous thrombosis. Science Translational Medicine, 14(660), eabj7465. https://doi.org/10.1126/scitranslmed.abj7465
MLA 9
Nayak, Lalitha V., et al. “A targetable pathway in neutrophils mitigates both arterial and venous thrombosis.” Science Translational Medicine, vol. 14, no. 660, 2022, p. eabj7465. https://doi.org/10.1126/scitranslmed.abj7465.
Chicago
Nayak, Lalitha V., David R. Sweet, Asha Thomas, Stephanie D. Lapping, Kenneth A Kalikasingh, Annmarie Madera, Vinesh Vinayachandran, et al. 2022. “A targetable pathway in neutrophils mitigates both arterial and venous thrombosis.” Science Translational Medicine 14 (660): eabj7465. https://doi.org/10.1126/scitranslmed.abj7465.
Harvard
Nayak, L. V. et al. (2022) ‘A targetable pathway in neutrophils mitigates both arterial and venous thrombosis’, Science Translational Medicine, 14(660), p. eabj7465. doi:10.1126/scitranslmed.abj7465.
IEEE
L. V. Nayak et al., “A targetable pathway in neutrophils mitigates both arterial and venous thrombosis,” Science Translational Medicine, vol. 14, no. 660, p. eabj7465, 2022, doi: 10.1126/scitranslmed.abj7465.
BibTeX
@article{nayak2022targetable,
title = {{A targetable pathway in neutrophils mitigates both arterial and venous thrombosis}},
author = {Nayak, Lalitha V. and Sweet, David R. and Thomas, Asha and Lapping, Stephanie D. and Kalikasingh, Kenneth A and Madera, Annmarie and Vinayachandran, Vinesh and Padmanabhan, Roshan and Vasudevan, Neelakantan T. and Myers, Jay and Huang, Alex Yee-Chen and Schmaier, Alvin H. and Mackman, Nigel and Liao, Xudong and Maiseyeu, Andrei and Jain, Mukesh K.},
journal = {Science Translational Medicine},
year = {2022},
volume = {14},
number = {660},
pages = {eabj7465},
doi = {10.1126/scitranslmed.abj7465},
url = {https://doi.org/10.1126/scitranslmed.abj7465}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 2 | |
| 2023 | 15 | |
| 2024 | 15 | |
| 2025 | 15 | |
| 2026 | 14 |
Its field-weighted citation impact is 6.74: it has been cited 6.74 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- arterial thrombosis
- venous thrombosis
- neutrophils
- KLF2
- antiphospholipid syndrome
- PSGL-1
- P-selectin
- neutrophil activation
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Nayak, L. V., Sweet, D. R., Thomas, A., Lapping, S. D., Kalikasingh, K. A., Madera, A., Vinayachandran, V., Padmanabhan, R., Vasudevan, N. T., Myers, J., Huang, A. Y.-C., Schmaier, A. H., Mackman, N., Liao, X., Maiseyeu, A., & Jain, M. K. (2022). A targetable pathway in neutrophils mitigates both arterial and venous thrombosis. Science Translational Medicine, 14(660), eabj7465. https://doi.org/10.1126/scitranslmed.abj7465
How many times has this paper been cited?
61 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the PDF from this page.
Who wrote this paper?
Lalitha V. Nayak, David R. Sweet, Asha Thomas, Stephanie D. Lapping, Kenneth A Kalikasingh, Annmarie Madera, Vinesh Vinayachandran, Roshan Padmanabhan, Neelakantan T. Vasudevan, Jay Myers, Alex Yee-Chen Huang, Alvin H. Schmaier and 4 more.
What is the DOI of this paper?
10.1126/scitranslmed.abj7465, permanently at https://doi.org/10.1126/scitranslmed.abj7465. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.